(Credit-Canva)
Prostate cancer is one of the most common cancers in men. About 1 in 8 men are at risk of prostate cancer diagnosis and about 1 in 44 men die due to it, according to the American Cancer Society. While the rates of deaths related to prostate cancer have declined in recent years, this decline rate has slowed down, meaning that more cancers are being detected at an advanced stage.
However, a new clinical trial could help turn these statistics around. This is not a new medicine, this treatment regime is based on two FDA-approved drugs, and it is showing some promising results.
A new clinical trial shows that a combination of two drugs can dramatically help men whose prostate cancer has returned following surgery or radiation. This new therapy was found to cut the risk of death by more than 40% in this high-risk group.
The successful regimen combines the drug enzalutamide with the standard hormone therapy doctors typically prescribe. This dual approach resulted in a major reduction in deaths for patients with recurrent prostate cancer who previously had very few effective treatment options left.
The highly anticipated results were published in The New England Journal of Medicine (NEJM) and presented simultaneously at the European Society for Medical Oncology Congress (ESMO) on October 19.
The American Cancer Society estimates for 2025 are about 313,780 new cases of prostate cancer diagnosis and 35,770 deaths from it. One of the best ways to combat cancer is early diagnosis, however, missing symptoms is very easy. With the help of this medicinal regime, many people can avoid facing harsh cancer treatments.
The clinical trial was extensive, involving over 1,000 patients from hundreds of medical facilities across 17 different countries. All of the men were diagnosed with a condition known as high-risk biochemically recurrent prostate cancer.
This specific diagnosis is given to men whose blood levels of a protein called PSA (Prostate Specific Antigen) suddenly start to climb rapidly after they've had surgery or radiation. Doctors use the PSA protein to track the cancer, and a quick rise is a strong signal that the cancer is highly likely to come back and spread to other areas, most often the bones or spine. Without a truly powerful treatment, these patients face a high risk of developing widespread cancer and possibly dying from their disease.
In the study, the men were randomly put into three groups: one group got only the standard hormone therapy, one got only enzalutamide, and the third got the combination of both drugs. After the men were tracked for eight years, the group that received the combination treatment had a death rate that was 40.3% lower than the other two groups.
These excellent results are expected to quickly change the way doctors treat this type of cancer everywhere. The drug enzalutamide is already approved by government agencies and listed in major cancer treatment guidelines based on previous studies.
These latest results will likely make the recommendation even stronger, confirming that this drug combination should become the standard treatment for men with this aggressive, recurrent prostate cancer. This outcome supports earlier research and will significantly improve how doctors care for their patients.
While researchers are working on ways to improve prostate cancer treatment, one must know how to spot any symptoms of it as well. According to the National Health Service UK, prostate cancer has no symptoms at first. However, as the cancer starts growing on the outer parts of the prostate, you may notice some problems.
Some symptoms of advanced prostate cancer include
(Credit-Canva)
Our bodies may hit their peak strength, skin firmness, and ability to have children when we are young adults, but new studies have found that our brains actually perform their best much later in life.
As people get old, the perception that they are no longer capable of making decisions or that they stop remembering things becomes rampant. These assumptions can lead to age-based discrimination, such as favoring younger employees over older, experienced ones. However, how true is this assumption? Do we actually start experiencing cognitive decline as soon as we come close to midlife?
A study published in the journal Intelligence looked at data measuring abilities like reasoning, memory, processing speed, general knowledge, and emotional intelligence across different ages.
The findings challenge the idea that we’re mentally sharpest in our 20s. Instead, the research found that our overall psychological functioning peaks much later, typically between ages 55 and 60.
According to the lead study author, our mental ability doesn't really start to drop until around age 65, and the decline only gets noticeably faster after age 75.
The research also looked closely at five main personality traits: being outgoing, handling stress well, being careful and organized, being open to new things, and being agreeable.
The researchers discovered that many of these traits also reach their best levels later in life. For example, conscientiousness (being thorough and disciplined) peaks around age 65, and emotional stability (staying calm and balanced) is highest around age 75.
The study further found that our ability to make good moral judgments improves with age, and our skill at making rational decisions (resisting poor cognitive biases) may continue to improve even into our 70s and 80s. This helps explain why many top jobs in business and government are often held by people in their 50s and early 60s.
This latest research focused on real, measurable psychological strengths that directly lead to better performance in the real world. Many of these strengths, like better judgment and decision-making, are vital for people in leadership positions.
However, despite these clear signs that older people are at their psychological peak, they still often face major challenges when looking for a new job or trying to stay in their current one.
Even though there is a law (the Age Discrimination in Employment Act of 1967) that protects people aged 40 and over from unfair treatment in hiring and firing, discrimination still happens in reality. An Ageism in the Workplace Survey found that a huge 90% of workers over age 40 have experienced ageism at work. Many employers wrongly believe that someone in their mid-50s is a poor long-term investment.
The hope is that these new findings will make it clear that companies need to adopt fair hiring and retention practices that include older workers. As the author noted, history is full of people who achieved their biggest successes well past the age society usually labels as the "peak."
Credits: Canva
Respiratory virus season is upon the United States as colder months arrive, bringing an expected rise in cases of COVID-19, influenza, and RSV. In its annual outlook, the Centers for Disease Control and Prevention (CDC) predicts that peak hospitalizations from these viruses during the 2025–26 season will be similar to last year. Public health experts speaking to ABC News have emphasised that vaccination remains the most effective way to protect against severe illness. Below, we answer common questions about the RSV vaccine for anyone seeking guidance.
Who Can Get An RSV Immunization?
According to the CDC, RSV vaccines are recommended for adults aged 75 and older, as well as those between 50 and 74 who have a higher risk of severe illness. Studies suggest that a single dose provides protection for at least two years in older adults. For infants, protection can be achieved either by vaccinating mothers during pregnancy or by giving babies an antibody shot after birth to help prevent severe RSV infection.
Eligible adults can receive the RSV vaccine at any time, though late summer and early fall are generally considered the best period, according to the CDC. For expectant mothers, the vaccine is usually available between September and January, while the antibody shot for infants is typically recommended from October through March.
For those with insurance, the RSV vaccine may be fully covered. Without insurance, the shot can cost around $350, according to Dupont. “Patient assistance programs are available that can significantly reduce out-of-pocket costs,” Dupont added.
Does RSV Vaccine Have Any Side Effect?
Like all vaccines, the RSV shot can have side effects. Common ones include pain, redness, or swelling at the injection site, as well as fever, headache, fatigue, and muscle or joint aches. Serious side effects are rare but can occur. Fainting may also happen after the shot, and observation may be advised to prevent injury.
(Credit-Canva)
Many people are choosing to become parents later in their lives. Whether it is due to financial reasons or due to difficulty conceiving, etc. However, many people bring up the ‘biological clock’ argument. While it is possible to have pregnancy later in life, there are some health implications, not just for the mother, but also for the child. Many people often place this responsibility on women. However, a new study shows that fathers who have children later in life may also risk passing down harmful mutations.
New research shows that as men get older, their sperm collects harmful mutations, which can raise the risk of health issues in their children.
Researchers in the UK studied sperm samples from 81 healthy men, ranging in age from 24 to 75. Using a highly accurate testing method, the team found that harmful changes, or mutations, build up in sperm over time. Simply put, the older a man is, the more his sperm’s genetic quality declines.
The study identified over 40 genes that cause the sperm stem cells to mutate. This genetic process is known as "selfish sperm."
What's most alarming is that these harmful mutations don't just accumulate; they are actually favored during the creation of new sperm. This means that sperm cells carrying the mutations multiply and out-compete the healthy sperm, leading to a higher proportion of damaged cells. This process can lead to a two to three times higher risk of passing on disease-causing mutations. The study measured the percentage of sperm carrying disease-causing mutations and found a clear increase with age:
These mutated genes are linked to developmental disorders and inherited syndromes that can increase the risk of certain cancers. The mutations that increase most sharply as the father ages are connected to severe neurodevelopmental disorders in children, including some conditions on the autism spectrum.
The study confirmed that specific rare genetic disorders, such as Apert, Noonan, and Costello syndromes, are rooted in this “selfish sperm” phenomenon.
These findings are particularly important today because older fatherhood is becoming much more common. The number of fathers over the age of 40 nearly doubled between 1972 and 2015.
This trend concerns the given related data: a recent analysis found that fathers over 40 had a 51% greater chance of having a child diagnosed with autism compared to fathers under 30.
While these results highlight an increased risk that older fathers should be aware of, the researchers stress that more study is needed. They also point out that while the number of mutated sperm increases with age, not all of them will lead to a successful pregnancy, as some may prevent fertilization or cause miscarriage.
© 2024 Bennett, Coleman & Company Limited